Top Facebook Posts of 2019
As 2019 comes to a close, we look back on our most popular Facebook posts from throughout the year. All of these stories are the result of Massey’s mission—to save and improve the lives of people affected by cancer. Please join us in this mission and follow us on Facebook to keep up with our activities in the new year.
Massey surgical oncologist Dr. Giao Phan spoke with ABC 8News about a clinical trial that evaluates the effectiveness and safety of an adoptive cell-transfer therapy to treat patients with metastatic melanoma.
We celebated Oncology Nursing Month in May, as well as National Nurses Week and Nurses Day. On this day, we honored Massey's acute care oncology nursing team. This hard-working group provides exceptional and compassionate care to our patients in the VCU Medical Center Critical Care Hospital.
Massey researcher Paula Bos, Ph.D., was awarded $650,000 in grants by the Susan G. Komen Breast Cancer Foundation and The V Foundation for Cancer Research! Bos will use the funds to study how immune cells impact breast cancer brain metastasis in an effort to develop more effective therapeutic strategies that minimize harsh side effects.
Dr. Brian Kaplan, director of Massey's Pancreas and Biliary Neoplasm Program, spoke with NBC12 about signs and symptoms of pancreatic cancer and possible treatment options.
Massey researchers M. Imad Damaj, Ph.D., and David A. Gewirtz, Ph.D., were awarded more than $1.1 million by the National Cancer Institute to research alternative cancer treatment options as a means to inform novel therapies that can prevent or suppress nerve damage triggered by chemotherapy.
Dr. John McCarty, director of Massey’s Cellular Immunotherapies and Transplant Program, visited ABC 8News - WRIC's Showcase Richmond to discuss CAR T-cell therapy and how this cutting-edge form of cellular immunotherapy is being used at Massey to treat advanced blood cancers.
Massey researchers led by Dr. Chuck Harrell have identified key biological pathways that regulate the spread of tumor cells to vital organs. These findings may have a significant influence on the development of new therapies that slow or prevent breast cancer metastasis.
An international clinical trial, co-led by Massey physician-scientist Charles Geyer, M.D., found that the drug T-DM1 reduces the risk of recurrence in patients with HER2-positive early-stage breast cancer by a remarkable 50 percent. Dr. Geyer spoke with ABC 8News - WRIC about how he expects these groundbreaking results will impact the future of breast cancer treatment.
Coming from a lineage of world-class canoeists, sports have always been a part of Dodge Havens' life, even in the midst of undergoing treatment for stage 4 kidney cancer. Despite more than five years of aggressive treatments, he still maintains a positive outlook and continues to do the things that bring him joy. In this video, Dodge describes his journey and shares the knowledge he has gained throughout it all.
VCU Massey Cancer Center physicians were again recognized in Richmond Magazine’s annual list of “Top Docs.” The selections were the result of a survey that asked Richmond-area physicians who they would recommend in a range of specialties.